Finerenone use and incident psoriasis in patients with type 2 diabetes and chronic kidney disease: A retrospective cohort study using the TriNetX network

Wu-Lung Chuang, Ruey-Hwang Chou, Yuan-Hung Wang, I-Ju Tsai, Cheng-Li Lin, Der-Yang Cho, Kuang-Hsi Chang · 2026

Read Finerenone use and incident psoriasis in patients with type 2 diabetes and chronic kidney disease: A retrospective cohort study using the TriNetX network by Wu-Lung Chuang, Ruey-Hwang Chou, Yuan-Hung Wang, I-Ju Tsai, Cheng-Li Lin, Der-Yang Cho, Kuang-Hsi Chang (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13470444.txt.

Description

Wu-Lung Chuang and colleagues write in 2026, in letter form, about whether a kidney drug might lower new cases of psoriasis in people with diabetes. Finerenone improves kidney and heart outcomes in type 2 diabetes with chronic kidney disease, and its anti inflammatory action makes a skin effect plausible. Clinical evidence on the question had been thin.

Using a global research network of health records, the team matched about seventeen hundred finerenone users one to one with nonusers of similar health. New psoriasis appeared in thirteen users against sixty three nonusers during follow up. The adjusted risk estimate for users came out near a fifth of the nonuser risk, with a tight margin. Survival curves showed a clearly higher psoriasis free share in the finerenone group.

Catalog record

CREATORWu-Lung Chuang, Ruey-Hwang Chou, Yuan-Hung Wang, I-Ju Tsai, Cheng-Li Lin, Der-Yang Cho, Kuang-Hsi Chang
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE5075
LICENSEhttps://creativecommons.org/licenses/by/4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/article/MED/PMC13470444

Browse the full library · About the Tower of Babel